Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Published Date: 11 Sep 2024

The c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an acceptable safety profile in patients of Asian race with c-Met protein-overexpressing, epidermal growth factor receptor ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer

2.

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

3.

Nanoparticle vaccine prevents multiple cancers and stops metastasis in mice

4.

Encounters matter in cancer care: Health care professionals can play a key role in restoring patients' sense of control

5.

A prostate cancer risk prediction algorithm could help target men at highest risk


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot